Publication date: 6 April 2017
Source:Journal of Ethnopharmacology, Volume 201
Author(s): Xiangying Zhang, Jianbo Ding, Chunyan Gou, Tao Wen, Li Li, Xiaojun Wang, Huasheng Yang, Dan Liu, Jinli Lou, Dexi Chen, Feng Ren, Xiuhui Li
Ethnopharmacological relevanceThe Qingchangligan formula, a traditional Chinese medicine comprising five herbs, is useful for treatment of patients with liver failure; however, its protective and regulatory mechanisms remain elusive.Aim of the studyTo test the hypothesis that the Qingchangligan formula protects mice against acute liver failure by inhibiting liver inflammation.Materials and methodsAcute liver failure (ALF) was induced by intraperitoneal injection of D-GalN (700mg/kg) plus LPS (10μg/kg). The Qingchangligan formula was administered to mice in three doses of 50mg/kg (on day 1, day 2, and day 3) prior to D-GalN/LPS injection by intragastric administration. The mice in different groups were sacrificed at 6h after D-GalN/LPS injection, and liver samples and blood were collected for analysis.ResultsAdministration of the Qingchangligan formula not only ameliorated liver injury, as evidenced by reduced transaminase levels and well-preserved liver architecture, but also decreased the lethality in ALF mice. Moreover, in the ALF model, pretreatment with the Qingchangligan formula alleviated liver inflammation and decreased hepatocyte apoptosis. Further demonstrating the protective effects of the Qingchangligan formula, we found that pretreatment with the Qingchangligan formula reduced the expression of inflammatory cytokines by decreasing the expression of components of the mitogen-activated protein kinase (MAPK) pathway and promoting autophagy in vitro and in vivo.ConclusionsOur findings demonstrated that the Qingchangligan formula exerts a protective effect against the pathophysiology of ALF, especially in regulating liver inflammation, and provide a rationale for using the Qingchangligan formula as a potential therapeutic strategy to ameliorate ALF.
Graphical abstract
http://ift.tt/2muSzDG
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου